EVGN / Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates

Evogene (EVGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.2 more_horizontal

Evogene's wholly-owned subsidiary Casterra Ag has received initial purchase orders worth $11.3 million for its proprietary castor plant seeds, which w more_horizontal

Evogene Ltd (NASDAQ:EVGN ) Q1 2023 Earnings Conference Call May 18, 2023 9:00 AM ET Company Participants Rachel Tamara - Evident, Head of Investor Rel more_horizontal

Evogene (EVGN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.2 more_horizontal

Evogene Ltd. (NASDAQ:EVGN ) Q4 2022 Earnings Conference Call March 9, 2023 9:00 AM ET Company Participants Ofer Haviv - Chief Executive Officer Eyal R more_horizontal

Evogene's subsidiary Casterra has developed proprietary genomically modified, high-yield & high oil-content Castor seed varieties. In September 2022 t more_horizontal

Evogene (EVGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). more_horizontal

Dr. Elran Haber to participate in the Industry Leaders opening panel  at this premier Microbiome conference REHOVOT, Israel , June 15, 2022 /PRNewsw more_horizontal